Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

632 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Treatment with aromatase inhibitors stimulates the expression of epidermal growth factor receptor-1 and neuregulin 1 in ER positive/HER-2/neu non-amplified primary breast cancers.
Flågeng MH, Larionov A, Geisler J, Knappskog S, Prestvik WS, Bjørkøy G, Lilleng PK, Dixon JM, Miller WR, Lønning PE, Mellgren G. Flågeng MH, et al. Among authors: miller wr. J Steroid Biochem Mol Biol. 2017 Jan;165(Pt B):228-235. doi: 10.1016/j.jsbmb.2016.06.011. Epub 2016 Jun 22. J Steroid Biochem Mol Biol. 2017. PMID: 27343990
Low residual proliferation after short-term letrozole therapy is an early predictive marker of response in high proliferative ER-positive breast cancer.
Bedard PL, Singhal SK, Ignatiadis M, Bradbury I, Haibe-Kains B, Desmedt C, Loi S, Evans DB, Michiels S, Dixon JM, Miller WR, Piccart MJ, Sotiriou C. Bedard PL, et al. Among authors: miller wr. Endocr Relat Cancer. 2011 Nov 14;18(6):721-30. doi: 10.1530/ERC-11-0180. Print 2011 Dec. Endocr Relat Cancer. 2011. PMID: 21984694
Aromatase expression and outcomes in the P024 neoadjuvant endocrine therapy trial.
Ellis MJ, Miller WR, Tao Y, Evans DB, Chaudri Ross HA, Miki Y, Suzuki T, Sasano H. Ellis MJ, et al. Among authors: miller wr. Breast Cancer Res Treat. 2009 Jul;116(2):371-8. doi: 10.1007/s10549-008-0161-8. Epub 2008 Oct 22. Breast Cancer Res Treat. 2009. PMID: 18941892 Free PMC article. Clinical Trial.
632 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page